Targeted lipidomics indicated that WMSZY’s anti-obesity effect may be linked to cholesterol metabolism, adipocyte lipolysis, lipid digestion, insulin resistance, and glycerolipid metabolism. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.